Oculis announces positive Phase II data on licaminlimab

Privately-held Swiss ophthalmology company Oculis has released positive results of the licaminlimab active-controlled, multicenter, randomized, parallel-group Phase II clinical trial assessing the effect of topical licaminlimab (OCS-02) on anterior chamber (AC) cell grade in patients with acute anterior uveitis (AAU).

The study, "Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study," is accessible on the National Institutes of Health (NIH) website  here, and has been published in Translational Vision Science & Technology (TVST), an ARVO journal, noted Oculis, which last month announced a deal with European Biotech Acquisition Corp (Nasdaq: EBAC), a special purpose acquisition company (SPAC), to combine the businesses and seek a public listing, which is expected to be completed in the first half of 2023.

Study details